PubMed Health⌕ Search

SEARCH · PubMed Health

Results for “Complement C8”

Explore indexed PubMed citations for clinical trials, systematic reviews and public health research. Read source abstracts and follow each citation to its original PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 91 records · Page 5Linked to original sources
PubMed1980

Binding of the eighth component of human complement to the soluble cytolytic complex is mediated by its beta subunit.

The noncovalently associated alpha-gamma and beta subunits of the eighth component of human complement (C8) were isolated and examined for their ability to recombine to form C8. Each subunit was also examined to determine its capability to interact independently with the C8 binding site on the soluble form of the cytolytic complex of complement. Results indicate that alpha-gamma and beta physically recombine in solution to form native C8 when mixed in equimolar amounts, a finding consistent with the concomitant appearance of C8 hemolytic activity. The ability of each subunit to interact independently with SC5b-7, the precursor of the soluble cytolytic complex which binds C8, was determined by sucrose density gradient analyses. It was found that alpha-gamma exhibits little affinity for SC5b-7, while the beta subunit readily binds to yield a stable complex of SC5b-7(beta). Interaction of beta was specific for the C8 binding site on SC5b-7 as evidenced by the ability to compete with C8. Results indicate that structural domains which mediate specific interaction of C8 with the nascent cytolytic complex are located in the beta subunit of this unusual protein.

Complement C8↗
PubMed1980

The eighth component of human complement. Purification and physicochemical characterization of its unusual subunit structure.

The eighth component of human complement (C8) has been purified in high yield from Cohn Fraction III and characterized with regard to its physicochemical properties and subunit structure. The purified product was found to be similar to functional C8 isolated from plasma or serum. Human C8 possesses a molecular weight of 151,000 and is composed of a 1:1:1 ratio of three nonidentical subunits: alpha (Mr = 64,000), beta (Mr = 64,000), and gamma (Mr = 22,000). These subunits occur as a covalently linked alpha-gamma dimer which is noncovalently associated with beta. After purification and characterization of alpha, beta, and gamma, each was found to possess different amino acid compositions and NH2-terminal sequences. Both alpha and beta subunits contain similar but exceptionally high percentages of hydrophobic aromatic amino acids. As measured by circular dichroism, the secondary structure of C8 contains 12% alpha-helix, 24% beta structure, and 64% unordered structure, values typical of globular proteins. Complete secondary structure, as well as hemolytic activity, can be recovered after exposure to 6 M guanidinium hydrochloride or 8 M urea. The alpha-gamma and beta subunits were dissociated and isolated in the presence of sodium dodecyl sulfate and after removal of detergent, neither was found to possess independent hemolytic activity. Significantly, activity equivalent to that of native C8 was generated when alpha-gamma and beta were recombined in an equimolar ratio. These results indicate that C8 is an atypical serum protein with regard to both its subunit structure and denaturation characteristics.

Amino Acids↗
PubMed1987

The eighth component of human complement: evidence that it is an oligomeric serum protein assembled from products of three different genes.

The eighth component of human complement (C8) consists of three nonidentical subunits arranged asymmetrically as a disulfide-linked alpha-gamma dimer and a noncovalently associated beta chain. Genetic studies of C8 polymorphisms established that alpha-gamma and beta are encoded at different loci. Implicit in this finding was the existence of two different genes and the likelihood that alpha-gamma would be synthesized in single-chain precursor form. However, recent characterization of cDNA clones revealed separate mRNAs for human alpha and beta but no evidence of a single-chain precursor for alpha-gamma. A cDNA clone containing the entire coding region for human gamma has now been characterized, and its sequence supports the existence of a separate gamma mRNA. Included are a consensus translation initiation sequence, an apparent initiation methionine, and a signal peptide. By use of cDNA probes specific for human alpha, beta, or gamma, analysis of poly(A) RNA from normal baboon liver revealed separate mRNAs of 2.5, 2.6, and 1.0 kilobases (kb), respectively. Parallel analysis of poly(A) RNA from rat liver identified mRNAs of 3.4, 2.3, and 0.9 kb. These results argue against the possibility that C8 is assembled from products of two different genes (alpha-gamma and beta) and suggest it is comprised of three different gene products (alpha, beta, and gamma) that undergo both covalent and noncovalent association to yield the mature protein.

Amino Acid Sequence↗
PubMed1995

The eighth component of human complement: molecular basis of C8A (C81) polymorphism.

Using an exon-specific polymerase chain reaction (PCR) followed by direct DNA sequence analysis we have analyzed the polymorphism of the alpha-chain of the eighth component of human complement (C8) at the DNA level. We found that two common alleles, C8A*A and C8A*B, are characterized by the substitution of a single amino acid (Gln to Lys), which is caused by a point mutation of a single nucleotide (C to A) in exon 3 at position 187 of the mature C8 alpha cDNA sequence. Based on this mutation, an allele-specific PCR was designed detecting the two alleles of C8A. We applied this method to type the C8A polymorphism using DNA samples from a Chinese Han population. The comparison with the data of protein typing of the same samples proved that the described method is efficient and reliable for the identification of C8A genotypes and may be valuable for further application in population studies and forensic science.

Alleles↗
PubMed2000

Lipocalins as biochemical markers of disease.

Lipocalins as biochemical markers of disease have been used extensively. The clinical indications relate to almost any field of medicine, such as inflammatory disease, cancer, lipid disorders, liver and kidney function. Some of the more well-known lipocalins that have been used as markers of disease are orosomucoid, Protein HC (alpha(1)-microglobulin), apolipoprotein D, retinol-binding protein, complement C8 gamma, prostaglandin D synthase and human tear prealbumin, and these markers will be briefly reviewed in this article. Emphasis, however, will be put on the description of another newly described lipocalin, i.e. human neutrophil lipocalin/neutrophil gelatinase-associated lipocalin (HNL/NGAL), since the body fluid measurement of HNL/NGAL was shown to be a superior means to distinguish between acute viral and bacterial infections and also to accurately reflect the activity and involvement of neutrophils in a variety of other diseases.

Acute-Phase Proteins↗
PubMed1993

The human complement component C8B gene: structure and phylogenetic relationship.

The eighth component of human complement (C8) is a serum protein that consists of three chains (alpha, beta and gamma), encoded by three separate genes, viz., C8A, C8B, and C8G. In serum, the beta-subunit is non-covalently bound to the disulfide-linked alpha-gamma subunit. Using a full-length C8 beta cDNA probe, we isolated several clones from human genomic lambda DNA libraries. Four lambda clones covering the complete cDNA sequence were characterized by TaqI restriction mapping and were "shotgun" subcloned into M13. C8 beta-cDNA-positive clones were partially sequenced to characterize the 12 exons of the gene with sizes from 69 to 347 bp. All intron-exon junctions followed the GT-AG rule. By using polymerase chain reaction (PCR) primers located in the adjacent intron sequences, all 12 exons of the C8B gene could be amplified from genomic DNA. All fragments showed the expected sizes. The sizes of eight introns could be determined by using primer pairs that amplified two exons and the enclosed intron, and by restriction mapping. These analyses and the insert sizes of the genomic lambda clones indicate that the C8B gene has a total size of approximately 40 kb. The polymorphic TaqI site of the C8B gene localized in intron 11 could be demonstrated by direct restriction fragment analysis of a PCR fragment containing exons 11 and 12, and the enclosed intron 11. Homology comparison of the C8B gene with C8A and C9 on the basis of the exon structure confirmed the ancestral relationship known from the protein level.

Base Sequence↗
PubMed1983

Determination of alternate pathway complement kinetics by electron spin resonance spectroscopy.

We describe a technic that measures the kinetics of the metabolic burst of peripheral blood neutrophils (PMN) by electron spin resonance (ESR) spin trapping. Using this technic, a functional assay for the kinetics of the alternate pathway complement cascade is developed. PMN were stimulated by phagocytosis of opsonized zymosan (OpZym) to undergo the metabolic burst and the resulting free hydroxyl radicals generated during the burst were trapped using 5,5-dimethyl-1-pyrroline-N-oxide (DMPO) to form a stable spin adduct. Rapid sequential measurements of the spin adduct concentration were made using a computer-controlled ESR spectrometer to follow the time course of the metabolic burst. Differences in the results obtained with OpZym and with PMN incubated with unopsonized zymosan (Zym) and serum yields information about the kinetics of opsonization. The kinetics of the alternate complement pathway opsonization in sera from normal and C8-deficient patients were compared and found not to be affected significantly by the absence of C8 complement protein.

Adult↗
PubMed1980

Recurrent meningococcal infections associated with a functional deficiency of the C8 component of human complement.

A patient is described who had a functional deficiency of the C8 complement component. His serum contained abnormal C8 which lacked some of the antigenic determinants of normal C8. The defect was associated with recurrent meningococcal infections due at different times to at least two strains. The patient's serum contained antibodies to meningococci and could induce phagocytosis and intracellular killing of the cocci by polymorphs. However, the serum was bactericidal only after the addition of C8-containing serum. As the patient did not give a history of susceptibility to other pyogenic organisms and has normal polymorph function, the circumstances of meningococcal infection must be unusual in that the plasma bactericidal activity critically determines the outcome: it may be that if large numbers of meningococci are not killed in the plasma, the polymorphs are overwhelmed.

Adolescent↗
PubMed1996

S-protein/vitronectin interaction with the C5b and the C8 of the complement membrane attack complex.

S-protein/vitronectin participates in the regulation of complement-mediated lysis by incorporating into the membrane attack complex C5b-9. Subsequently, soluble SC5b-7 and SC5b-9 macromolecules are not inserted into the membrane lipid bilayer nor induce lytic pore formation. Using a dot blot binding assay, it was determined that soluble S-protein/vitronectin interacted with immobilized C5b and C8 among the five separately immobilized components (C5b, C6, C7, C8, C9) of the membrane attack complex. Those interactions imply a new model of the formation of the complement membrane attack complex and its regulation by S-protein/vitronectin.

Animals↗
PubMed1988

Detecting distant homologies of mosaic proteins. Analysis of the sequences of thrombomodulin, thrombospondin complement components C9, C8 alpha and C8 beta, vitronectin and plasma cell membrane glycoprotein PC-1.

Recognition of homologies may give hints about the structure and function of proteins; therefore, we are developing strategies to aid sequence comparisons. Detecting homology of mosaic proteins is especially difficult since the modules constituting these proteins are usually distantly related and their homology is not readily recognized by conventional computer programs. In the present work we show that the rules of the evolution of mosaic proteins can guide the identification of modules of mosaic proteins and can delineate the group of sequences in which the presence of homologous sequences may be expected. By this approach we can concentrate the search for homology to a limited group of sequences; thus ensuring a more intense and more fruitful search. The power of this approach is illustrated by the fact that it could detect homologies not identified by earlier methods of sequence comparison. In this paper we show that thrombomodulin contains a domain homologous with animal lectins, that complement components C9, C8 alpha and C8 beta have modules homologous with one of the repeat units of thrombospondin and that the somatomedin B module of vitronectin is homologous with the internal repeats of plasma cell membrane glycoprotein PC-1.

Amino Acid Sequence↗
PubMed2001

Complement factor I deficiency associated with recurrent meningitis coinciding with menstruation.

BACKGROUND: Complement (C) factor I deficiency is a rare immunodeficiency state frequently associated with recurrent pyogenic infections in early infancy. This deficiency causes a permanent uncontrolled activation of the alternative pathway resulting in massive consumption of C3. PATIENT: A 23-year-old woman with monthly recurrent meningitis episodes, mostly in the perimenstrual period, since August 1999. Previously, at age 16 years, she had meningococcal sepsis, also coinciding with menstruation. OBJECTIVES: To study the patient and her family to elucidate the molecular defects in the pedigree and to evaluate her clinical evolution. RESULTS: We describe clinical, immunological, and treatment follow-up during this period. First, we characterized the existence of a total complement factor I deficiency defined by undetectable levels by enzyme immunosorbent assay. This total deficiency was also found in her sister. Her parents and brother had approximately half of the normal levels. In addition, the patient had very low levels of C3; factor B; and an important reduction of factor H, properdin, C5, C7, and C8 complement components. Additional studies in the patient's sera evidenced high levels of immune complexes containing C1q and immunoglobulin (Ig) G, as well as C3b/factor H, C3b/properdin, C3b/IgG, and properdin/IgG complexes. Treatment with prophylactic antibiotics, antiestrogen medication, plasma infusions, or intravenous immunoglobulin has been unsuccessful in avoiding consecutive meningitis episodes. CONCLUSION: For the first time to our knowledge, these data present an unusual relationship between meningitis episodes and menstruation in factor I immunodeficiency.

Adolescent↗
PubMed1990

Regulation of the membrane attack complex of complement. Evidence that C8 gamma is not the target of homologous restriction factors.

Inability of the membrane attack complex of C (C5b-9) to efficiently lyse E from the same species has been attributed to one or more membrane-associated proteins that are collectively called homologous restriction factors. These include a 65,000 Mr protein referred to as the C8 binding protein or homologous restriction factor and a 20,000 Mr protein referred to as P-18, HRF20, CD59 Ag, or MIRL. Both are found on nucleated cells as well as E and both protect against complement-mediated lysis by interfering with C8 and/or C9 function within C5b-9. The exact mechanism by which these factors restrict activity is unknown but studies with purified C8 binding protein suggest they may interact specifically with the gamma subunit of C8. To determine directly if gamma is the target of restriction factors, a derivative of human C8 lacking this subunit was evaluated for its potential to lyse homologous cells. This derivative (C8') was previously shown to be functionally equivalent to normal C8 in a heterologous sheep E system. Here, it is compared to normal C8 by using human E as target cells. Results indicate no difference between the ability of C8 and C8' to incorporate into HuEAC1-7, to mediate subsequent C9 binding and to promote hemolysis. Thus, the presence or absence of gamma has no effect on homologous restriction of C5b-9, therefore gamma cannot be the primary target of homologous restriction factors.

Blood Proteins↗
PubMed1976

Human deficiency of the eighth component of complement. The requirement of C8 for serum Neisseria gonorrhoeae bactericidal activity.

The serum of a 23-yr-old woman with prolonged disseminated gonococcal infection syndrome failed to normally promote hemolysis of sensitized sheep red blood cells (RBC). The patient's serum was deficient in the eight component of complement (C8) as determined by functional assays, immunoelectrophoresis, and quantitative immunoprecipitation. Functional titers of each of her other complement components were normal. No serum inhibitors of C8 were detected. The patient's serum supported activation of both the classical and alternate complement pathways. Her fresh serum lacked any bactericidal activity against Neisseria gonorrhoeae, but addition of purified C8 or complement donor serum restored bactericidal activity as well as RBC hemolytic activity. Her serum gave normal opsonization of yeast particles and staphylococci and had normal capacity to coat sensitized RBC with C8 and C4 and to generate chemotactic activity. No defects were observed in the patient's blood coagulation mechanisms. Complement-mediated bacterial lysis may be important in human defense against bacteremic Neisseria infections.

Adult↗
PubMed1999

Identification of a 220-kDa membrane tumor-associated antigen by human anti-UK114 monoclonal antibodies selected from the immunoglobulin repertoire of a cancer patient.

Human monoclonal antibodies (HuMAb) specific for a 14-kDa perchloric acid-soluble protein (defined as UK114) were produced by somatic fusion of the human-mouse myeloma K6H6/B5 with Epstein-Barr virus-transformed peripheral B lymphocytes from a cancer patient previously treated with UK101 preparations, containing the UK114 protein. Three IgM-secreting clones were selected on the criteria of specificity for the purified UK114 protein immobilized onto plastic and adapted to grow in a serum-free medium. The reactivity of these antibodies showed a broad distribution pattern restricted to fresh tumor tissues and tumor cell lines, mainly of the adenocarcinoma type. None of the normal cells, nonmalignant cell lines, and normal tissues surrounding the neoplastic lesions were reactive. The immunochemical analysis of the target antigens showed that the HuMAb recognize a molecule of 220 kDa selectively expressed by the surface of tumor cells, as well as a cytoplasmic 14-kDa protein. The 220-kDa antigen was different from other tumor-associated antigens with similar molecular mass and, so far, unique. In the presence of human complement, two of three HuMAb are cytotoxic for tumor cells expressing the 220-kDa surface antigen. The tumor specificity and the lytic ability attributed to these HuMAb are promising features for the exploration of future clinical applications.

Animals↗